NASDAQ: NTRA
Natera Inc Stock

$261.91+1.17 (+0.45%)
Updated Jun 26, 2026
NTRA Price
$261.91
Fair Value Price
-$191.09
Market Cap
$37.51B
52 Week Low
$131.81
52 Week High
$271.23
P/E
-161.67x
P/B
21.14x
P/S
11.32x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.50B
Earnings
-$226.32M
Gross Margin
65.1%
Operating Margin
-11.28%
Profit Margin
-9%
Debt to Equity
0.47
Operating Cash Flow
$211M
Beta
1.44
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A

NTRA Overview

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine NTRA's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Diagnostic & Research

Industry Rating
C
NTRA
Ranked
#26 of 43

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$28.82A
$176.55B
$118.17B
View Top Diagnostic & Research Stocks

Be the first to know about important NTRA news, forecast changes, insider trades & much more!

NTRA News

Overview

Due Diligence Score

Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NTRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NTRA ($261.91) is overvalued by 237.06% relative to our estimate of its Fair Value price of -$191.09 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NTRA ($261.91) is not significantly undervalued (237.06%) relative to our estimate of its Fair Value price of -$191.09 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NTRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NTRA due diligence checks available for Premium users.

Valuation

NTRA fair value

Fair Value of NTRA stock based on Discounted Cash Flow (DCF)

Price
$261.91
Fair Value
-$191.09
Undervalued by
237.06%
NTRA ($261.91) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NTRA ($261.91) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NTRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

NTRA price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-161.67x
Industry
14.36x
Market
12.39x

NTRA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
21.14x
Industry
3.82x
NTRA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

NTRA's financial health

Profit margin

Revenue
$696.6M
Net Income
-$85.1M
Profit Margin
-12.2%
NTRA's Earnings (EBIT) of -$282.18M... subscribe to Premium to read more.
Interest Coverage Financials
NTRA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$2.6B
Liabilities
$840.4M
Debt to equity
0.47
NTRA's short-term assets ($1.65B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NTRA's short-term assets ($1.65B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NTRA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NTRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$40.2M
Investing
-$32.1M
Financing
$3.8M
NTRA's operating cash flow ($211.02M)... subscribe to Premium to read more.
Debt Coverage Financials

NTRA vs Diagnostic & Research Stocks

TickerZen RatingMarket Cap1d %P/EP/B
NTRAC$37.51B+0.45%-161.67x21.14x
WATC$36.76B-0.66%47.45x2.40x
AB$38.41B+0.37%27.20x5.39x
IQVC$31.90B+2.53%23.51x5.13x
IDXXB$43.50B-0.62%40.26x27.96x

Natera Stock FAQ

What is Natera's quote symbol?

(NASDAQ: NTRA) Natera trades on the NASDAQ under the ticker symbol NTRA. Natera stock quotes can also be displayed as NASDAQ: NTRA.

If you're new to stock investing, here's how to buy Natera stock.

What is the 52 week high and low for Natera (NASDAQ: NTRA)?

(NASDAQ: NTRA) Natera's 52-week high was $271.23, and its 52-week low was $131.81. It is currently -3.44% from its 52-week high and 98.7% from its 52-week low.

How much is Natera stock worth today?

(NASDAQ: NTRA) Natera currently has 143,215,382 outstanding shares. With Natera stock trading at $261.91 per share, the total value of Natera stock (market capitalization) is $37.51B.

Natera stock was originally listed at a price of $22.74 in Jul 2, 2015. If you had invested in Natera stock at $22.74, your return over the last 10 years would have been 1,051.76%, for an annualized return of 27.68% (not including any dividends or dividend reinvestments).

How much is Natera's stock price per share?

(NASDAQ: NTRA) Natera stock price per share is $261.91 today (as of Jun 26, 2026).

What is Natera's Market Cap?

(NASDAQ: NTRA) Natera's market cap is $37.51B, as of Jun 28, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Natera's market cap is calculated by multiplying NTRA's current stock price of $261.91 by NTRA's total outstanding shares of 143,215,382.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.